1. Gilead Sold $873 Million Worth of its Antiviral COVID-19 Treatment Even Though Data on its Success Remains Mixed

    Gilead Sold $873 Million Worth of its Antiviral COVID-19 Treatment Even Though Data on its Success Remains Mixed
    • Gilead posted its first numbers detailing how much money the pharmaceutical company has made through Veklury, a COVID-19 antiviral treatment.
    • Gilead sold $873 million worth of Veklury, also known as remdesivir, in three months.
    • The FDA authorized Veklury as the first antiviral treatment approved to treat COVID-19 patients.
    • Studies on the effectiveness of Veklury present mixed results...
    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Partner Publications, Question of The Week, Sponsored Content
  2. Quotes

    1. I'm extremely grateful that a therapy exists that has been validated with all of the rigor required for an FDA approval.
  3. Topics Mentioned

  4. Authors